Moderna, Inc. (BVMF:M1RN34)

Brazil flag Brazil · Delayed Price · Currency is BRL
7.16
+0.15 (2.14%)
At close: Nov 11, 2025
2.14%
Market Cap55.26B
Revenue (ttm)11.90B
Net Income (ttm)-16.61B
Shares Outn/a
EPS (ttm)-42.91
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume189,644
Average Volume92,144
Open6.87
Previous Close7.01
Day's Range6.86 - 7.16
52-Week Range6.22 - 14.89
Beta1.11
RSI51.19
Earnings DateNov 6, 2025

About Moderna

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, su... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 5,800
Stock Exchange Brazil Stock Exchange
Ticker Symbol M1RN34
Full Company Profile

Financial Performance

In 2024, Moderna's revenue was $3.24 billion, a decrease of -52.75% compared to the previous year's $6.85 billion. Losses were -$3.56 billion, -24.46% less than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.